Differentiating the next generation of GLP-1 therapies

Beyond weight loss: Exploring the clinical development strategies shaping the future of obesity treatment

The GLP-1 therapeutic landscape is evolving rapidly. With increasingly effective treatments entering development, achieving significant weight loss alone may no longer be enough to differentiate the next generation of obesity therapies.

For biopharmaceutical sponsors, the challenge is shifting toward demonstrating sustained clinical benefit, improving tolerability and treatment persistence, and generating evidence of meaningful outcomes beyond weight reduction.

In this on-demand presentation, Davide Garrisi examines the latest developments in GLP-1 therapies and explores the clinical and operational considerations that may influence future obesity drug development programs.

Looking beyond weight loss to demonstrate lasting value

As obesity therapies continue to advance, sponsors must consider how to differentiate their assets through evidence of long-term efficacy, safety, tolerability and broader cardiometabolic benefits.

Watch this expert presentation to gain insights into the evolving GLP-1 landscape and the considerations shaping next-generation obesity clinical development.

Learn more about our metabolic clinical development experience.